Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T cell
Researches from the Laboratory of biocatalysis of IBCH RAS in collaboration with the Scripps Research Institute and Xiamen University demonstrated for the first time that targeting the CDR3 regions of malignant T cell clones by cell therapy is a viable approach to eliminate leukemia cells. The study was supported by RSF and published in Leukemia.
26 апреля 2019 года